|Podcasts|December 17, 2021
Diversity and Disruption in Clinical Research
Capital infusion, Nasdaq debut ignite ‘agile’ approach to attracting patients without bounds
Advertisement
David Coman, CEO of Science 37, a decentralized clinical trials platform company, discusses his organization’s recent public debut via the SPAC route, how that’s powering its mission to enable universal and diverse access to clinical research, and the potential of “agile clinical trial” designs in disrupting the future drug development landscape for the better.
The latest episode of The Pharmaceutical Commerce Podcast is available directly on SoundCloud.
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
BoomRx Expands Access to Oral Semaglutide and Tirzepatide Using Nanoemulsion Delivery
2
The Hidden Economics of Health Insurance Affordability
3
Pharma Pulse: Novartis Warns of Trade Fragmentation; Hospital M&A Hits Record Low; Copay Shock Warning
4
Evaluate’s 2026 Pharma Forecast Signals Cautious Recovery, Rising M&A, and GLP-1 Market Shifts
5